Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00809)
Name
Adenosine
Synonyms    Click to Show/Hide the Synonyms of This API
adenosine; 58-61-7; Adenocard; Adenoscan; Adenine riboside; beta-D-Adenosine; Nucleocardyl; Adenosin; Boniton; Sandesin; Myocol; Adenine nucleoside; Adenocor; beta-Adenosine; 9-beta-D-Ribofuranosyladenine; 9-beta-D-Ribofuranosidoadenine; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; Adenosin [German]; USAF CB-10; 9beta-D-Ribofuranosyladenine; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; Ade-Rib; Caswell No. 010B; Adenosine [USAN:BAN]; beta-D-Ribofuranoside, adenine-9; 6-Amino-9beta-D-ribofuranosyl-9H-purine; SR 96225; (2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 3H-adenosine; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; NSC 7652; MFCD00005752; UNII-K72T3FS567; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; Adenosine (Adenocard); CHEBI:16335; AI3-52413; 9H-Purin-6-amine, 9beta-D-ribofuranosyl-; CHEMBL477; SR-96225; D-Adenosine; ADO; beta-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; adenine-D-ribose; K72T3FS567; CCRIS 2557; Adenosine, 99+%; 5536-17-4; Adenine-9-beta-D-ribofuranoside; NCGC00023673-05; Polyadenosine; Pallacor; Polyriboadenosine; DSSTox_CID_2558; DSSTox_RID_76628; DSSTox_GSID_22558; alpha-Adenosine; L-Adenosine; .beta.-D-Adenosine; CAS-58-61-7; Adenocard (TN); Adenoscan (TN); SMR000058216; MEDR-640; Adenine 9-beta-D-arabinofuranoside; Adenosine, homopolymer; Adenosine (JAN/USP); SR-05000001981; EINECS 200-389-9; Adenine-beta-D-arabinofuranoside; NSC 627048; 9-.beta.-d-Ribofuranosyladenine; NSC7652; Adenogesic; Adenosine [USAN:USP:BAN]; adenosine group; Adenin riboside; NSC-7652; .beta.-D-Ribofuranoside, adenine-9; 9-.alpha.-D-Arabinofuranosyladenine; MFCD00065471; NSC627048; b-D-Adenosine; HSDB 7774; SUN-Y4001; N6-Methylado; 1dgm; 1odi; 2fqy; 2ydo; 3axz; 4cki; 4ckj; Adenosine,(S); adenosine-N-15N; 5682-25-7; adenosine-8-13C; adenosine-9-15N; beta-delta-Adenosine; [U-14C]adenosine; 6-Amino-9.beta.-D-ribofuranosyl-9H-purine; PubChem9306; 41547-82-4; 2gl0; 3ay0; 4pd9; Adenosine, >=99%; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; Spectrum2_001257; Spectrum3_000288; cid_191; SCHEMBL731; bmse000061; bmse000996; Epitope ID:140947; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; 9-ss-D-Ribofuranosyladenine; BSPBio_001796; .beta.-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; cid_60961; MLS000069638; MLS002153227; MLS006010946; SPECTRUM1500107; Adenine-9-ss-D-ribofuranoside; REGID_for_CID_60961; SPBio_001194; adenine-9beta-D-Ribofuranoside; GTPL2844; 9beta-delta-Ribofuranosyladenine; DTXSID1022558; BDBM14487; KBio3_001296; 9-beta-delta-Ribofuranosyladenine; EA6C60C2-6AFB-4264-A2F0-541373DB950E; 9-.beta.-D-Ribofuranosidoadenine; 9-beta-delta-Ribofuranosidoadenine; adenine-9beta-delta-Ribofuranoside; Bio1_000437; Bio1_000926; Bio1_001415; HMS1920A13; HMS2091G13; HMS2235E24; HMS3884O04; Pharmakon1600-01500107; 3080-29-3; ACT02616; ALBB-032827; AMY30083; XYA; ZINC2169830; 9-beta-delta-Arabinofuranosyladenine; Tox21_110891; adenosine-2-13C-N,1,3-15N3; ANW-32994; CCG-38824; NSC755857; s1647; AKOS015888594; Tox21_110891_1; AC-8229; AM83931; DB00640; MCULE-7071766082; NSC-755857; SDCCGMLS-0003108.P003; 9-?-D-Ribofuranosyl-9H-purin-6-amine; 9beta-D-ribofuranosyl-9H-Purin-6-amine; NCGC00023673-03; NCGC00023673-04; NCGC00023673-06; NCGC00023673-07; NCGC00023673-10; NCGC00023673-20; NCGC00178869-03; 30143-02-3; 9-? -D-Ribofuranosyl-9H-purin-6-amine; AC-27494; AS-12664; AT-11502; ST009496; Adenosine, Vetec(TM) reagent grade, 98%; SBI-0206673.P002; 9beta-delta-ribofuranosyl-9H-Purin-6-amine; AB0012292; DB-022408; 6-Amino-9beta-delta-ribofuranosyl-9H-purine; 9-.beta.-D-Ribofuranosyl-9H-purin-6-amine; 9-beta-delta-Ribofuranosyl-9H-purin-6-amine; A0152; 9H-Purin-6-amine, 9-.beta.-d-ribofuranosyl-; C00212; D00045; S-3476; AB00384349-11; AB00384349_13; AB00384349_14; Adenosine, BioReagent, suitable for cell culture; Q190012; SR-05000001981-1; SR-05000001981-2; Z1741978458; 1-(6-amino-9H-purin-9-yl)-1-deoxy-beta-D-Ribofuranose; Adenosine, European Pharmacopoeia (EP) Reference Standard; Formycin A, from Streptomyces kaniharaensis, >=98% (HPLC); 1-(6-amino-9H-purin-9-yl)-1-deoxy-beta-delta-Ribofuranose; Adenosine, United States Pharmacopeia (USP) Reference Standard; Adenosine, Pharmaceutical Secondary Standard; Certified Reference Material; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 142796-17-6; 158749-77-0; 177030-94-3; 244769-76-4
Clinical Status
Approved
PubChem CID
60961
Formula
C10H13N5O4
Canonical SMILES
C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N
InChI
1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1
InChIKey
OIRDTQYFTABQOQ-KQYNXXCUSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=60961"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 267.24 Topological Polar Surface Area 140
XlogP -1.1 Complexity 335
Heavy Atom Count 19 Rotatable Bond Count 2
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 8
Full List of Drug Formulations (DFMs) Containing This API
          Adenosine 0.04% cream Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Water; Cetyl Ethylhexanoate; Hydrogenated Polyisobutene; Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer; Propylene Glycol; Glycerin; Sodium Hyaluronate; Fructan; Anemarrhena Asphodeloides Root Extract; Nelumbium Speciosum Flower Extract; Lecithin; Tocopheryl Acetate; Disodium Edta; Chlorphenesin; 1, 2-Hexanediol; Phenoxyethanol; Fragrance
                   Dosage Form Cream
                   Company Bio-S Co. Ltd
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Hyaluronate sodium DIG Info Leukemia MT4 cells (EC50 = 5.4 ug.mL-1) [1]
Tocopheryl acetate DIG Info Prostate cancer LNCaP cells (EC50 = 38000 nM) [2]
Tocopheryl acetate DIG Info Breast cancer MCF7 cells (IC50 > 500000 nM) [3]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [4]
Soybean lecithin DIG Info Albendazole monooxygenase (IC50 = 6.61 mg.mL-1) [4]
          Adenosine 6mg/2ml injectable Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Sodium Chloride; Water
                   Dosage Form Injectable
                   Company Hf Acquisition Co. Dba Health First
          Adenosine 60mg/20ml injectable Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Sodium Chloride; Water
                   Dosage Form Injectable
                   Company Teva Parenteral Medicines
References
1 Preparation and anti-HIV activity of O-acylated heparin and dermatan sulfate derivatives with low anticoagulant effect. J Med Chem. 1993 Nov 12; 36(23):3546-55.
2 First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents. Bioorg Med Chem. 2007 May 15; 15(10):3413-21.
3 Design and synthesis of analogs of vitamin E: antiproliferative activity against human breast adenocarcinoma cells. Bioorg Med Chem Lett. 1998 Sep 22; 8(18):2433-8.
4 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.